FGEN: FibroGen, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 55.92
Enterprise Value ($M) 57.86
Book Value ($M) -201.70
Book Value / Share -2.00
Price / Book -0.28
NCAV ($M) -221.59
NCAV / Share -2.20
Price / NCAV -0.25

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -0.29
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.16
Current Ratio 1.28

Balance Sheet (mrq) ($M)
Current Assets 244.53
Assets 264.42
Liabilities 466.12
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
11-14 13G/A Armistice Capital, Llc 6.77 -30.36
11-12 13G/A Vanguard Group Inc 5.85 0.00
11-12 13G/A Primecap Management Co/ca/ 9.87 -31.51
07-08 13G/A BlackRock, Inc. 2.40 -66.56
02-14 13G/A Point72 Asset Management, L.P. 1.70 -73.83

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q
2024-08-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q
2024-05-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q
2024-02-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-15 200,349 746,515 26.84
2025-01-14 397,687 1,033,347 38.49
2025-01-13 351,592 1,391,897 25.26
2025-01-10 623,444 2,377,656 26.22

(click for more detail)

Similar Companies
EWTX – Edgewise Therapeutics, Inc. EXEL – Exelixis, Inc.
FDMT – 4D Molecular Therapeutics, Inc. GBIO – Generation Bio Co.
GERN – Geron Corporation


Financial data and stock pages provided by
Fintel.io